Program
peginterferon alfa-2b
Also written as “Peginterferon alfa-2b”, “peginterferon alfa-2b (SCH 54031)” and “PEG-Intron”.
Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatitis B, Chronic · Melanoma · Hepatitis B, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 450 open or running | phase 4since Nov 15, 2005 | Mar 29, 2000 | none ahead |
| Tanabe Pharma | 30 open or running | phase 3since Nov 2, 2011 | Feb 24, 2008 | none ahead |
| Xiamen Amoytop Biotech | 32 open or running | phase 3since Apr 12, 2021 | Apr 12, 2021 | May 31, 2029NCT06707922 |
| FGK Clinical Research | 10 open or running | phase 4since Jul 11, 2006 | Jul 11, 2006 | none ahead |
Also a collaborator on its studies: Vertex Pharmaceuticals, Integrated Therapeutics Group, Johnson & Johnson and ViroPharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Mar 29, 2000.
- May 1, 2012Phase 3 study in Hepatitis C, ChronicMerck · NCT01590225
- May 24, 2012Phase 4 study in Hepatitis C, ChronicMerck · NCT01606800 · 45 enrolled
- Jul 5, 2012Phase 1 study in MelanomaMerck · NCT01636960 · 9 enrolled
- Jul 11, 20122 phase 3 studiesMerck · NCT01641926, NCT01641666
- Aug 30, 2012Phase 1 study in Hepatitis C, ChronicMerck · NCT01678131 · 31 enrolled
- Nov 12, 2012Phase 4 study in Hepatitis BMerck · NCT01727271
- Sep 13, 2013Phase 3 study in Hepatitis C, ChronicMerck · NCT01945294 · 257 enrolled
- Mar 14, 2014Phase 2 study in Carcinoma, Renal CellMerck · NCT02089685 · 295 enrolled
- Jun 2, 2014Phase 2 study in MelanomaMerck · NCT02155322 · 33 enrolled
- May 15, 20183 phase 3 studiesMerck · NCT03537274, NCT03547154, NCT03552549
- May 31, 2018Phase 1 study in NeoplasmsMerck · NCT03554005 · 29 enrolled
- Apr 12, 2021Xiamen Amoytop Biotech’s first study: phase 3 study in Hepatitis B, ChronicNew to Xiamen Amoytop BiotechXiamen Amoytop Biotech · NCT04846491 · 475 enrolled · China
- Jul 27, 2024Phase 2 study in Thrombocythemia, EssentialXiamen Amoytop Biotech · NCT06552429 · 27 planned · China
- Nov 24, 2024No phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922 · 350 planned · China
Ahead
- May 31, 2029Primary completion: no phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922
TargetBeta
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| peginterferon alfa-2arule | Hoffmann-La Roche | phase 4 | 100 |
| Interferon beta-1arule | Biogen | phase 4 | 60 |
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06707922Hepatitis B, Chronic · China | – | By invitation | Xiamen Amoytop Biotech | May 31, 2029 | 350 |
| NCT06552429Thrombocythemia, Essential · China | 2 | Recruiting | Xiamen Amoytop Biotech | Oct 26, 2025 | 27 |
| NCT04846491Hepatitis B, Chronic · China | 3 | Completed | Xiamen Amoytop Biotech | Nov 30, 2023 | 475 |
| NCT03554005Neoplasms | 1 | Completed | Merck | Mar 16, 2001 | 29 |
| NCT03552549Melanoma | 3 | Terminated | Merck | Feb 19, 2001 | 126 |
| NCT03547154Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | Terminated | Merck | Feb 20, 2001 | 344 |
| NCT03537274Hepatitis C | 3 | Completed | Merck | Jul 23, 1999 | 1,224 |
| NCT02155322Melanoma | 2 | Completed | Merck | Mar 21, 2016 | 33 |
| NCT02089685Carcinoma, Renal Cell | 2 | Completed | Merck | Apr 1, 2021 | 295 |
| NCT01945294Hepatitis C, Chronic | 3 | Completed | Merck | Aug 5, 2015 | 257 |
| NCT01727271Hepatitis B | 4 | Withdrawn | Merck | Aug 2017 | 0 |
| NCT01678131Hepatitis C, Chronic | 1 | Completed | Merck | Aug 27, 2013 | 31 |
| NCT01641926Hepatitis B, Chronic | 3 | Terminated | Merck | Jan 21, 2016 | 402 |
| NCT01641666Hepatitis C, Chronic | 3 | Withdrawn | Merck | Sep 2016 | 0 |
| NCT01636960Melanoma | 1 | Terminated | Merck | Mar 26, 2014 | 9 |
| NCT01606800Hepatitis C, Chronic | 4 | Terminated | Merck | Jan 26, 2015 | 45 |
| NCT01590225Hepatitis C, Chronic | 3 | Withdrawn | Merck | Aug 18, 2021 | 0 |
| NCT01547312Hepatitis C, Chronic | 1 | Withdrawn | Merck | Nov 2012 | 0 |
| NCT01468584Hepatitis C, Chronic · Japan | 3 | Completed | Tanabe Pharma | Sep 2013 | 10 |
| NCT01466192Hepatitis C, Chronic · Japan | 3 | Completed | Tanabe Pharma | Aug 2013 | 108 |
| NCT01432535Renal Insufficiency | 1 | Completed | Merck | Aug 2012 | 25 |
| NCT01081158Hepatitis C, Chronic | 1 | Completed | Merck | Aug 2008 | 41 |
| NCT00811967Hepatitis C, Chronic | 3 | Terminated | Merck | May 2006 | 50 |
| NCT00787371Hepatitis C, Chronic | 2 | Completed | Merck | Jul 2006 | 69 |
| NCT00761735Hepatitis C, Chronic | 3 | Completed | Merck | Jan 2013 | 94 |
| NCT00759109Carcinoma, Hepatocellular | 3 | Completed | Merck | Nov 2009 | 150 |
| NCT00724620Hepatitis C, Chronic | 4 | Completed | Merck | Feb 2008 | 103 |
| NCT00687544Hepatitis C, Chronic | 4 | Terminated | Merck | Sep 2008 | 11 |
| NCT00687219Hepatitis C, Chronic | 3 | Completed | Merck | Oct 2010 | 102 |
| NCT00686881Hepatitis C, Chronic | 3 | Terminated | Merck | Feb 2011 | 261 |
| NCT00686790Hepatitis D, Chronic | 3 | Completed | Merck | May 2009 | 68 |
| NCT00686777Hepatitis C, Chronic | 4 | Completed | Merck | Dec 2010 | 75 |
| NCT00686517Hepatitis C | 3 | Completed | Merck | Dec 2010 | 130 |
| NCT00630058Hepatitis C · Japan | 1 | Completed | Tanabe Pharma | Mar 2009 | 20 |
| NCT00536263Hepatitis B, Chronic | 3 | Completed | Merck | Nov 2009 | 671 |
| NCT00493805Hepatitis C, Chronic | 4 | Terminated | Merck | Oct 2009 | 59 |
| NCT00457418Melanoma | 1 | Completed | Merck | May 27, 2008 | 32 |
| NCT00441584Hepatitis C, Chronic | 3 | Terminated | Merck | Jun 2008 | 117 |
| NCT00423800Hepatitis C, Chronic | 3 | Terminated | Merck | Oct 2009 | 56 |
| NCT00381017Hepatitis C | 3 | Withdrawn | Merck | 0 | |
| NCT00378599Hepatitis C, Chronic | 3 | Completed | Merck | Jul 2009 | 125 |
| NCT00371761Hepatitis B | 3 | Completed | Merck | Feb 2009 | 25 |
| NCT00351403Hepatitis C, Chronic · Germany | 4 | Completed | FGK Clinical Research | Jan 2010 | 390 |
| NCT00302081Hepatitis C, Chronic | 3 | Completed | Merck | Apr 2008 | 696 |
| NCT00265395Hepatitis C, Chronic | 3 | Completed | Merck | May 2008 | 1,428 |
| NCT00255034Hepatitis C, Chronic | 4 | Terminated | Merck | Jun 2008 | 146 |
| NCT00237484Hepatitis C, Chronic | 3 | Completed | Merck | Jun 30, 2011 | 89 |
| NCT00104052Hepatitis C, Chronic | 3 | Completed | Merck | Nov 2007 | 107 |
| NCT00049842Hepatitis C, Chronic | 3 | Completed | Merck | Oct 2009 | 540 |
| NCT00048724Hepatitis C, Chronic | 3 | Completed | Merck | Apr 2008 | 631 |
| NCT00035360HIV Infections | 3 | Completed | Merck | Oct 2003 | 49 |
| NCT00005012HIV Infections · United States, Puerto Rico | 2 | Completed | Merck | 250 |
How it is read
Names in the registry
- “Peginterferon alfa-2b”, 10 entries
- “peginterferon alfa-2b (SCH 54031)”, 5 entries
- “PEG-Intron”, 4 entries
- “PegIntron (peginterferon alfa-2b)”, 4 entries
- “Peginterferon alfa-2b injection”, 3 entries
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 31 studies
- Hepatitis C, 6 studies
- Hepatitis B, Chronic, 4 studies
- Melanoma, 4 studies
- Hepatitis B, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.